Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Increased plasma levels of soluble TNF receptors 1 and 2 in bipolar depression and impact of lithium treatment

Full text
Author(s):
Teixeira, Antonio L. [1] ; de Souza, Rafael T. [2] ; Zanetti, Marcus V. [2, 3] ; Brunoni, Andre R. [2] ; Busatto, Geraldo F. [3] ; Zarate, Jr., Carlos A. [4] ; Gattaz, Wagner F. [2] ; Machado-Vieira, Rodrigo [2, 4]
Total Authors: 8
Affiliation:
[1] Univ Fed Minas Gerais, Sch Med, Interdisciplinary Lab Med Investigat, Belo Horizonte, MG - Brazil
[2] Univ Sao Paulo, Inst & Dept Psychiat, Neurosci Lab, LIM 27, Sao Paulo - Brazil
[3] Univ Sao Paulo, Inst & Dept Psychiat, Lab Psychiat Neuroimaging, LIM 21, Sao Paulo - Brazil
[4] NIMH, Expt Therapeut & Pathophysiol Branch, NIH, Bethesda, MD 20892 - USA
Total Affiliations: 4
Document type: Journal article
Source: HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL; v. 30, n. 1, p. 52-56, JAN 2015.
Web of Science Citations: 11
Abstract

ObjectiveTNF system (TNF and its soluble receptors sTNFR1 and 2) has been investigated as a potential molecular target in bipolar disorder. The aim of the study was to compare plasma levels of these receptors in unmedicated bipolar depressed patients compared with healthy controls, and to evaluate the effects of a 6-week lithium treatment on sTNFR1 and sTNFR2 levels. MethodsThe study enrolled 29 patients with unmedicated bipolar disorder in a major depressive episode and 27 matched controls. Patients had blood collected at baseline and after 6weeks of lithium treatment. The concentration of sTNFRs was measured by ELISA. ResultssTNFR1 and sTNFR2 levels were significantly increased in bipolar depression in comparison with healthy subjects. Lithium treatment did not significantly change sTNFR1 and sTNFR2 levels from baseline to endpoint. There was no correlation between improvement in depressive symptoms and the change in sTNFR1 or sTNFR1 levels. ConclusionThese results reinforce the involvement of an activated immune response system in the pathophysiology of bipolar disorder, with no impact of lithium treatment on the related biomarkers. Copyright (c) 2014 John Wiley \& Sons, Ltd. (AU)

FAPESP's process: 09/14891-9 - Longitudinal study on the neuroprotective and neurotrophic effects of lithium in bipolar disorder: identification of cellular and molecular targets clinically relevant
Grantee:Rodrigo Machado-Vieira
Support Opportunities: Research Grants - Young Investigators Grants